652 related articles for article (PubMed ID: 23480100)
41. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.
Osta WA; Chen Y; Mikhitarian K; Mitas M; Salem M; Hannun YA; Cole DJ; Gillanders WE
Cancer Res; 2004 Aug; 64(16):5818-24. PubMed ID: 15313925
[TBL] [Abstract][Full Text] [Related]
42. EpCAM-Targeting Aptamer Radiotracer for Tumor-Specific PET Imaging.
Li F; Zeng Z; Hamilton D; Zu Y; Li Z
Bioconjug Chem; 2021 Jun; 32(6):1139-1145. PubMed ID: 34014641
[TBL] [Abstract][Full Text] [Related]
43. Aptamer selection and applications for breast cancer diagnostics and therapy.
Liu M; Yu X; Chen Z; Yang T; Yang D; Liu Q; Du K; Li B; Wang Z; Li S; Deng Y; He N
J Nanobiotechnology; 2017 Nov; 15(1):81. PubMed ID: 29132385
[TBL] [Abstract][Full Text] [Related]
44. Predicting the aptamer SYL3C-EpCAM complex's structure with the Martini-based simulation protocol.
Shang X; Guan Z; Zhang S; Shi L; You H
Phys Chem Chem Phys; 2021 Mar; 23(12):7066-7079. PubMed ID: 33496283
[TBL] [Abstract][Full Text] [Related]
45. Cell-SELEX-based selection of aptamers that recognize distinct targets on metastatic colorectal cancer cells.
Li WM; Bing T; Wei JY; Chen ZZ; Shangguan DH; Fang J
Biomaterials; 2014 Aug; 35(25):6998-7007. PubMed ID: 24857291
[TBL] [Abstract][Full Text] [Related]
46. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.
Patriarca C; Macchi RM; Marschner AK; Mellstedt H
Cancer Treat Rev; 2012 Feb; 38(1):68-75. PubMed ID: 21576002
[TBL] [Abstract][Full Text] [Related]
47. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases.
Cimino A; Halushka M; Illei P; Wu X; Sukumar S; Argani P
Breast Cancer Res Treat; 2010 Oct; 123(3):701-8. PubMed ID: 20012351
[TBL] [Abstract][Full Text] [Related]
48. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
49. Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.
Subramanian N; Kanwar JR; Kanwar RK; Krishnakumar S
Nucleic Acid Ther; 2015 Dec; 25(6):317-22. PubMed ID: 26334953
[TBL] [Abstract][Full Text] [Related]
50. Dual-Multivalent-Aptamer-Conjugated Nanoprobes for Superefficient Discerning of Single Circulating Tumor Cells in a Microfluidic Chip with Inductively Coupled Plasma Mass Spectrometry Detection.
Zhang X; Wei X; Men X; Wu CX; Bai JJ; Li WT; Yang T; Chen ML; Wang JH
ACS Appl Mater Interfaces; 2021 Sep; 13(36):43668-43675. PubMed ID: 34473482
[TBL] [Abstract][Full Text] [Related]
51. In silico design and validation of high-affinity RNA aptamers targeting epithelial cellular adhesion molecule dimers.
Bell DR; Weber JK; Yin W; Huynh T; Duan W; Zhou R
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8486-8493. PubMed ID: 32234785
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of EpCAM-positive disseminated tumor cells in rectal cancer patients with stage I disease.
Dhayat S; Sorescu S; Vallböhmer D; Kraus S; Baldus SE; Rehders A; Kröpil F; Krieg A; Knoefel WT; Stoecklein NH
Am J Surg Pathol; 2012 Dec; 36(12):1809-16. PubMed ID: 23060348
[TBL] [Abstract][Full Text] [Related]
53. Role of the EpCAM (CD326) in prostate cancer metastasis and progression.
Ni J; Cozzi PJ; Duan W; Shigdar S; Graham PH; John KH; Li Y
Cancer Metastasis Rev; 2012 Dec; 31(3-4):779-91. PubMed ID: 22718399
[TBL] [Abstract][Full Text] [Related]
54. Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines.
Sterzynska K; Kempisty B; Zawierucha P; Zabel M
Folia Histochem Cytobiol; 2012; 50(4):534-41. PubMed ID: 23264216
[TBL] [Abstract][Full Text] [Related]
55. De Novo Evolution of an Antibody-Mimicking Multivalent Aptamer via a DNA Framework.
Tang L; Huang M; Zhang M; Pei Y; Liu Y; Wei Y; Yang C; Xie T; Zhang D; Zhou R; Song Y; Song J
Small Methods; 2023 Jun; 7(6):e2300327. PubMed ID: 37086150
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
57. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
[TBL] [Abstract][Full Text] [Related]
58. LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging.
Roy K; Kanwar RK; Kanwar JR
Biomaterials; 2015 Dec; 71():84-99. PubMed ID: 26318819
[TBL] [Abstract][Full Text] [Related]
59. Novel RNA aptamers targeting gastrointestinal cancer biomarkers CEA, CA50 and CA72-4 with superior affinity and specificity.
Pan Q; Law COK; Yung MMH; Han KC; Pon YL; Lau TCK
PLoS One; 2018; 13(10):e0198980. PubMed ID: 30303958
[TBL] [Abstract][Full Text] [Related]
60. Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX.
Kunii T; Ogura S; Mie M; Kobatake E
Analyst; 2011 Apr; 136(7):1310-2. PubMed ID: 21321690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
